Amiodarone 

1. CLASSIFICATION 

Amiodarone = Class III antiarrhythmic (Vaughan-Williams classification)

Class

Action

Class I

Na⁺ channel blockade

Class II

β-blocking effect

Class III

K⁺ channel blockade (main)

Class IV

Ca²⁺ channel blockade

 2. MECHANISM OF ACTION 

  1. K⁺ channel blockade (Phase 3)
    • repolarization time
    • QT interval
    • refractory period prevents re-entry circuits
  1. Na⁺ channel blockade
    • conduction velocity (especially in ischemic tissue)
  1. Ca²⁺ channel blockade
    • AV node conduction
  1. Non-competitive β-blockade
    • sympathetic drive

 3. HEMODYNAMIC PROFILE 

Parameter

Effect

HR

AV conduction

BP

  (IV due to solvent, vasodilation)

Contractility

Mild

Coronary flow

  • Safe in LV dysfunction / cardiogenic shock (relative)
  • Much safer than other antiarrhythmics (e.g., flecainide)
  • Safest antiarrhythmic in structural heart disease
  • Prefer central line (peripheral phlebitis)
  • Dilute properly (avoid hypotension from solvent)
  • Avoid rapid bolus in unstable BP
  • Watch for drug accumulation in prolonged ICU stay

4. INDICATIONS 

 A. Cardiac Arrest (ACLS – American Heart Association)

Scenario

Role

VF / pulseless VT (shock refractory)

Drug of choice

After 3rd shock

300 mg IV bolus

 B. Ventricular Arrhythmias

  • Sustained VT (stable/unstable)
  • Electrical storm
  • Post-MI VT

 Preferred when:

  • Structural heart disease
  • LV dysfunction

 C. Supraventricular Arrhythmias

  • Atrial fibrillation (AF) with:
    • Hemodynamic instability
    • Heart failure
  • Atrial flutter
  • AVRT / WPW ( careful)

D. ICU-Specific Uses

  • Post-cardiac surgery AF
  • Sepsis-associated AF
  • Rate + rhythm control when β-blockers contraindicated

 5. DOSING IN ICU

 Cardiac Arrest (VF/pVT)

  • 300 mg IV bolus
  • Repeat 150 mg if needed

 Stable VT / AF

Loading:

  • 150 mg IV over 10 min

Infusion:

  • 1 mg/min × 6 hrs
  • then 0.5 mg/min

 Max: ~2.2 g/24 hr

Oral Conversion

  • 800–1200 mg/day (loading)
  • Maintenance: 100–200 mg/day

 6. PHARMACOKINETICS 

Feature

Details

Lipophilicity

Very high

Volume of distribution

Massive

Half-life

20–60 days (!!)

Onset (IV)

Rapid

 Clinical implication:

  • Accumulates in tissues toxicity even after stopping

7. ADVERSE EFFECTS 

 Pulmonary (MOST SERIOUS)

  • Interstitial pneumonitis
  • Pulmonary fibrosis
  • ARDS

 Mortality high STOP drug immediately

Cardiac

  • Bradycardia
  • AV block
  • QT prolongation
  • Torsades (rare vs others)

 CNS

  • Tremor
  • Ataxia
  • Peripheral neuropathy

 Dermatological

  • Photosensitivity
  • Blue-gray skin discoloration

 Ocular

  • Corneal deposits (common)
  • Optic neuropathy (rare)

 Thyroid 

Because of iodine content:

Type

Mechanism

Hypothyroidism

Wolff-Chaikoff effect

Hyperthyroidism

Jod-Basedow / thyroiditis


 Hepatic

  • LFTs
  • Hepatitis

 8. MONITORING

System

Test

Thyroid

TSH (baseline + 6 monthly)

Liver

LFT

Lung

CXR / PFT

Cardiac

ECG (QT interval)

Eye

Ophthalmology if symptoms

 9. DRUG INTERACTIONS 

Amiodarone = CYP inhibitor

Drug

Effect

Warfarin

INR

Digoxin

toxicity

Simvastatin

myopathy

QT drugs

torsades risk

 10. CONTRAINDICATIONS

  • Severe sinus node disease
  • AV block (without pacemaker)
  • Severe hypotension
  • Thyroid disease (relative)

Arrhythmia

Amiodarone Role

Torsades de pointes

 Contraindicated

Pre-excited AF (WPW)

 Avoid

MAT

 Not preferred

Digoxin toxicity arrhythmias

 Avoid